The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.
Durvalumab treatment over 12 months had no negative effect on key symptoms of lung cancer, physical function, global health status, or quality of life in patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following concurrent chemoradiotherapy.
The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.
Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.
Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.
Single-agent treatment with the PD-1 inhibitor pembrolizumab improved overall survival versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer and a PD-L1 expression level ≥1%.
Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel significantly improved overall survival compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.
Chad Pecot, MD, discusses the rapidly growing area of combination immunotherapy in non–small cell lung cancer.
The addition of atezolizumab to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer.
Heather Greene, NP, discusses the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting immune-related adverse events.